• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NOVELTY 研究中的可治疗特征。

Treatable traits in the NOVELTY study.

机构信息

Càtedra Salut Respiratoria, Universitat Barcelona, Barcelona, Spain.

Servei Pneumologia, Respiratory Institute, Hospital Clinic, Barcelona, Spain.

出版信息

Respirology. 2022 Nov;27(11):929-940. doi: 10.1111/resp.14325. Epub 2022 Jul 21.

DOI:10.1111/resp.14325
PMID:35861464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9795904/
Abstract

BACKGROUND AND OBJECTIVE

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of 'asthma', 'COPD' or 'asthma + COPD'.

METHODS

The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with 'asthma' (n = 5932, 52.8%), 'COPD' (n = 3898, 34.7%) or both ('asthma + COPD'; n = 1396, 12.4%).

RESULTS

The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with 'asthma', 'COPD' and 'asthma + COPD', respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity.

CONCLUSION

These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

摘要

背景与目的

哮喘和慢性阻塞性肺疾病(COPD)是两种常见且复杂的疾病,需要进行个性化管理。尽管已经提出了一种基于可治疗特征(TTs)的策略,但在真实环境中,这些 TTs 的流行程度及其与主治医生所确定的诊断标签和疾病严重程度的关系尚不清楚。我们评估了特定 TTs 的存在/缺失与“哮喘”、“COPD”或“哮喘+COPD”的诊断和严重程度之间的关系。

方法

作者从 NOVELTY 研究队列(NOVEL 观察性纵向研究;NCT02760329)中选择了 30 个常见的 TTs,这是一项大型(n=11226)的全球性研究,在初级保健诊所和专门中心中系统地收集了“哮喘”(n=5932,52.8%)、“COPD”(n=3898,34.7%)或两者(n=1396,12.4%)患者的真实数据。

结果

结果表明:(1)评估的 30 个 TTs 的患病率差异很大,“哮喘”、“COPD”和“哮喘+COPD”患者的平均(±标准差)分别为 4.6±2.6、5.4±2.6 和 6.4±2.8 个 TTs/患者(p<0.0001);(2)全球不存在大的地域差异,但初级诊所与专科诊所的 TTs 患病率不同;(3)许多 TTs 与疾病的诊断和严重程度相关,但也有许多不相关;(4)TTs 的存在和缺失形成了一种模式,被临床医生用于建立诊断并对其严重程度进行分级。

结论

这些结果提供了迄今为止在真实环境中对气道疾病患者 TTs 的最大和最详细的特征描述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/abe8d649b124/RESP-27-929-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/3ba9f0f309b8/RESP-27-929-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/dfaad74bb898/RESP-27-929-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/779ac0f75563/RESP-27-929-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/abe8d649b124/RESP-27-929-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/3ba9f0f309b8/RESP-27-929-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/dfaad74bb898/RESP-27-929-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/779ac0f75563/RESP-27-929-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dff/9795904/abe8d649b124/RESP-27-929-g002.jpg

相似文献

1
Treatable traits in the NOVELTY study.NOVELTY 研究中的可治疗特征。
Respirology. 2022 Nov;27(11):929-940. doi: 10.1111/resp.14325. Epub 2022 Jul 21.
2
Treatable Traits in Airway Disease: From Theory to Practice.气道疾病可治疗的特征:从理论到实践。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):713-723. doi: 10.1016/j.jaip.2023.01.011. Epub 2023 Feb 1.
3
Asthma masquerading as chronic obstructive pulmonary disease: a study of smokers fulfilling the GOLD definition of chronic obstructive pulmonary disease.哮喘伪装成慢性阻塞性肺疾病:一项符合 GOLD 慢性阻塞性肺疾病定义的吸烟者研究。
Respiration. 2011;82(1):19-27. doi: 10.1159/000323075. Epub 2011 Jan 29.
4
Treatable traits in pre-COPD: Time to extend the treatable traits paradigm beyond established disease.COPD 前可治疗特征:将可治疗特征范式扩展到既定疾病之外的时机。
Respirology. 2024 Jul;29(7):551-562. doi: 10.1111/resp.14760. Epub 2024 Jun 11.
5
[The NHG guidelines 'Adult asthma' and 'COPD'].[《荷兰卫生保健指南》之“成人哮喘”和“慢性阻塞性肺疾病”]
Ned Tijdschr Geneeskd. 2015;159:A9076.
6
Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.慢性阻塞性肺疾病 - 稳定期疾病的诊断和管理;基于临床表型的可治疗特征概念,采用个体化护理方法。捷克肺病和结核学会立场文件。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):325-356. doi: 10.5507/bp.2020.056.
7
Treatable Traits That Predict Health Status and Treatment Response in Airway Disease.可预测气道疾病健康状况和治疗反应的可治疗特征。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1255-1264.e2. doi: 10.1016/j.jaip.2020.09.046. Epub 2020 Oct 8.
8
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum.基于 NOVELTY 真实世界研究的聚类分析:哮喘-COPD 谱上的六个聚类。
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2803-2811. doi: 10.1016/j.jaip.2023.05.013. Epub 2023 May 23.
9
Breathomics and treatable traits for chronic airway diseases.呼吸组学与慢性气道疾病的可治疗特征。
Curr Opin Pulm Med. 2019 Jan;25(1):94-100. doi: 10.1097/MCP.0000000000000534.
10
Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group.主动和被动吸烟对在叙利亚初级保健就诊的女性哮喘和 COPD 的影响:世卫组织全球哮喘和呼吸疾病监测(GARD)调查小组的首次报告。
Int J Chron Obstruct Pulmon Dis. 2013;8:473-82. doi: 10.2147/COPD.S50551. Epub 2013 Oct 2.

引用本文的文献

1
Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits.慢性阻塞性肺疾病的新兴疗法:将创新与可治疗特征相对应
Lung. 2025 Sep 3;203(1):92. doi: 10.1007/s00408-025-00844-0.
2
Discovering Treatable Traits in Asthma: Toward More Precise Treatment.发现哮喘中可治疗的特征:迈向更精准的治疗
Open Respir Arch. 2025 Jun 6;7(3):100451. doi: 10.1016/j.opresp.2025.100451. eCollection 2025 Jul-Sep.
3
Treatable traits in interstitial lung disease: a narrative review.间质性肺疾病的可治疗特征:一篇叙述性综述

本文引用的文献

1
CT in COPD: To be or not to be.慢性阻塞性肺疾病中的CT:存在还是不存在。
Respirology. 2022 Apr;27(4):258-259. doi: 10.1111/resp.14233. Epub 2022 Feb 23.
2
Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort.BODE 队列中 COPD 患者的胸部 CT 评估合并症与全因死亡率风险。
Respirology. 2022 Apr;27(4):286-293. doi: 10.1111/resp.14223. Epub 2022 Feb 7.
3
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.全球哮喘倡议策略 2021:执行摘要和关键变化的理由。
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251335774. doi: 10.1177/17534666251335774. Epub 2025 May 3.
4
Treatable traits identified in Chinese patients hospitalized with AECOPD: A Multicenter Cohort Study.在中国因慢性阻塞性肺疾病急性加重(AECOPD)住院患者中识别出的可治疗特征:一项多中心队列研究。
Int J Med Sci. 2025 Apr 13;22(9):2227-2236. doi: 10.7150/ijms.111294. eCollection 2025.
5
Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.在一家成熟的基层医疗哮喘/慢性阻塞性肺疾病服务机构中,阻塞性肺疾病患者的可治疗特征
Int J Chron Obstruct Pulmon Dis. 2025 Apr 23;20:1189-1201. doi: 10.2147/COPD.S508281. eCollection 2025.
6
Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait?阻塞性肺疾病患者气道黏液栓的阻塞:一种新的可治疗特征?
ERJ Open Res. 2025 Jan 27;11(1). doi: 10.1183/23120541.00793-2024. eCollection 2025 Jan.
7
Integrating hot topics and implementation of treatable traits in asthma.整合哮喘的热点话题及可治疗特征的实施
Eur Respir J. 2024 Dec 5;64(6). doi: 10.1183/13993003.00861-2024. Print 2024 Dec.
8
Association of Lifestyle Behaviors with Quality of Life in Patients with COPD: A Cross-Sectional Study in Primary Care.慢性阻塞性肺疾病患者生活方式行为与生活质量的关联:一项初级保健中的横断面研究
J Clin Med. 2024 Aug 14;13(16):4793. doi: 10.3390/jcm13164793.
9
The treatable traits of asthma in pregnancy: a clinical audit.妊娠期哮喘的可治疗特征:一项临床审计
ERJ Open Res. 2024 Jun 17;10(3). doi: 10.1183/23120541.00748-2023. eCollection 2024 May.
10
Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY.真实环境中哮喘和/或慢性阻塞性肺疾病患者的症状与肺功能的关系:NOVEL 观察性纵向研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241254212. doi: 10.1177/17534666241254212.
J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S1-S18. doi: 10.1016/j.jaip.2021.10.001. Epub 2021 Oct 28.
4
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.支气管扩张症在成人中的放射学和临床诊断标准及定义:用于临床试验的国际共识建议。
Lancet Respir Med. 2022 Mar;10(3):298-306. doi: 10.1016/S2213-2600(21)00277-0. Epub 2021 Sep 24.
5
Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.迈向可治疗特征模型的护理,以管理阻塞性气道疾病。
Respir Med. 2021 Oct;187:106572. doi: 10.1016/j.rmed.2021.106572. Epub 2021 Aug 13.
6
Prioritizing Treatable Traits in Airways Disease.优先考虑气道疾病中可治疗的特征。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1265-1266. doi: 10.1016/j.jaip.2020.11.012.
7
Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.医生诊断的哮喘和/或慢性阻塞性肺疾病内部及之间的异质性:新型队列研究。
Eur Respir J. 2021 Sep 23;58(3). doi: 10.1183/13993003.03927-2020. Print 2021 Sep.
8
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.全球慢性阻塞性肺疾病诊断、管理和预防倡议。2020 年 GOLD 科学委员会关于 COVID-19 和慢性阻塞性肺疾病的报告。
Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36. doi: 10.1164/rccm.202009-3533SO.
9
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.复合 2 型生物标志物策略与基于症状风险的算法调整重度哮喘患者皮质类固醇剂量:一项多中心、单盲、平行组、随机对照试验。
Lancet Respir Med. 2021 Jan;9(1):57-68. doi: 10.1016/S2213-2600(20)30397-0. Epub 2020 Sep 8.
10
Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.吸入性类固醇、循环嗜酸性粒细胞、慢性气道感染与慢性阻塞性肺疾病肺炎风险:网络分析。
Am J Respir Crit Care Med. 2020 May 1;201(9):1078-1085. doi: 10.1164/rccm.201908-1550OC.